HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
Cubic Digital Technology
300344
HNAC Technology
300490
CN Stock MarketDetailed Quotes
000963 Huadong Medicine
- 33.28
- -0.45-1.33%
Not Open Feb 18 15:00 CST
58.38BMarket Cap18.18P/E (TTM)
33.89High33.20Low106.22KlotVolume33.73Open33.73Pre Close356.02MTurnover0.61%Turnover Ratio20.57P/E (Static)1.75BShares39.1552wk High2.65P/B58.30BFloat Cap25.6152wk Low37.10Limit Up1.75BShs Float52.20Historical High30.36Limit Down2.05%Amplitude-3.38Historical Low0.93Dividend TTM33.52Avg Price50.52KlotAsk2.79%Div YieldTTM100Lot Size50.69KlotBid
Huadong Medicine News
Huadong Pharmaceutical: An indicative announcement on the 2022 Restricted Stock Incentive Plan grants restricted stocks for the first time during the second period of lifting the sales restrictions and releasing the listing and circulation of restricted shares
Huadong Pharmaceutical: Announcement on Proposed Repurchase and Cancellation of Some Restricted Shares
Huadong Pharmaceutical: Supervisory Board\'s inspection opinions on the Company\'s 2022 Restricted Stock Incentive Plan granted restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
Huadong Pharmaceutical: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on Huadong Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan grants restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
Huadong Pharmaceutical: Announcement on the achievements of the 2022 Restricted Stock Incentive Plan to grant restricted stocks for the first time during the second period of lifting the sales restrictions and lifting the sales restrictions
Huadong Pharmaceutical: Legal Opinion of Zhejiang Tianze Law Firm on Huadong Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan grants restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
Huadong Pharmaceutical: Announcement on Adjusting the Repurchase Price of the 2022 Restricted Stock Incentive Plan
Huadong Pharmaceutical: An indicative announcement on the 2022 Restricted Stock Incentive Plan to reserve and grant restricted shares for the first time to lift the sales restriction period and release the listing and circulation of restricted shares
Huadong Pharmaceutical: Announcement on the achievements of the 2022 Restricted Stock Incentive Plan to reserve and grant restricted stocks the first time to lift the sales restrictions during the period of lifting the sales restrictions
Huadong Pharmaceutical: Legal Opinion of Zhejiang Tianze Law Firm on the 2022 Restricted Stock Incentive Plan of Huadong Pharmaceutical Co., Ltd. reserves and grants restricted stocks the first time to lift sales restrictions during the sales restriction period and the achievement of lifting the sales restrictions
Huadong Pharmaceutical: Supervisory Board\'s Verification Opinions on the Company\'s 2022 Restricted Stock Incentive Plan reserves and grants restricted shares for the first time during the sales restriction period to lift the sales restriction conditions
Huadong Pharmaceutical: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on the achievements of Huadong Pharmaceutical Co., Ltd. in the 2022 Restricted Stock Incentive Plan to reserve and grant restricted shares for the first time to lift the sales restriction period and lift the sales restriction conditions
Huadong Pharmaceutical: 2024 Semi-Annual Equity Distribution Implementation Notice
Huadong Pharmaceutical: Announcement on the completion of the cancellation of some restricted stock repurchases
Huadong Medicine: Announcement of the profit distribution plan for the first half of 2024.
Huadong Medicine: Announcement regarding the acquisition of 100% equity of Guizhou Hengba Pharmaceutical Co., Ltd.
Huadong Medicine: Announcement on the adjustment of the repurchase price of restricted stocks incentive plan for the year 2022 (updated)
Huadong Medicine: Legal Opinion of Zhejiang TianCe Law Firm on the Adjustment of Restricted Stock Grant Price and Redemption and Cancellation of Restricted Stocks of Huadong Medicine Co., Ltd.'s Restricted Stock Incentive Plan for 2022.
Huadong Medicine: Correction announcement regarding the repurchase and cancellation of restricted stocks.
Huadong Medicine: Announcement Regarding Repurchasing and Cancelling Certain Restricted Stocks (Updated)
